Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Current primary PTSD diagnosis based on DSM-IV criteria, with a minimum duration of 12 weeks since the traumatic event.~2. Between the age of 18 and 65.~Exclusion Criteria:~1. Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by the DSM-IV.~2. Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).~3. Current diagnosis of alcohol or substance dependence within the 3 previous months.~4. Unwilling or unable to discontinue current trauma-focused psychotherapy or psychotropic medication (at least 1 month medication free).~5. Ongoing intimate relationship with the perpetrator (in assault-related PTSD cases).~6. Unstable cardiovascular, autoimmune, endocrine, neurological, renal, hepatic, retinal, gastrointestinal, or hematological disorder or current seizure disorder.~7. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception for the duration of active treatment.~8. A history of hypersensitivity or allergy to MB.~9. Any condition possibly affecting drug absorption (e.g., gastrectomy).~10. Glucose-6-phosphate dehydrogenase deficiency.~11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that, in the judgment of the Medical Directors, would make the participant inappropriate for entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psychotherapy plus Methylene Blue, USP (Type: EXPERIMENTAL): None
- Psychotherapy Plus Placebo (Type: PLACEBO_COMPARATOR): None
- Delayed Psychotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).